Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer

Pau Riera, Anna C. Virgili, Juliana Salazar, Ana Sebio, María Tobeña, Ivana Sullivan, David Páez

    Research output: Contribution to journalArticleResearchpeer-review

    4 Citations (Scopus)


    © 2017, Macmillan Publishers Limited, part of Springer Nature. The role of vascular endothelial growth factor (VEGF) gene polymorphisms in the prognosis of colon cancer prognosis remains unclear. We evaluated the influence of 28 single-nucleotide polymorphisms in 12 genes in the VEGF pathway on the prognosis of 347 patients with stage II–III colon cancer. We found that rs9513070 (VEGFR1) and rs1137282 (KRAS) were associated with overall survival in stage II colon cancer patients (p = 0.025 and p = 0.001, respectively). When primary tumor location was considered, rs9513070 was also associated with relapse-free and overall survival (p = 0.033 and p = 0.031, respectively) in left colon cancer patients. Additionally, rs35251833 in the ITGAV gene correlated with relapse-free survival (p = 0.032). This study provides evidence that germline polymorphisms in VEGFR1, KRAS and ITGAV genes are associated with prognosis in stages II–III colon cancer patients. As stage and tumor location are correlated with prognosis, future genetic studies should stratify colon cancer patients according to these parameters.
    Original languageEnglish
    Pages (from-to)556-564
    JournalPharmacogenomics Journal
    Issue number4
    Publication statusPublished - 1 Jul 2018


    Dive into the research topics of 'Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer'. Together they form a unique fingerprint.

    Cite this